Lehmann BD - Search Results

1

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes.

Lehmann BD, Colaprico A, Silva TC, Chen J, An H, Ban Y, Huang H, Wang L, James JL, Balko JM, Gonzalez-Ericsson PI, Sanders ME, Zhang B, Pietenpol JA, Chen XS. Lehmann BD, et al. Nat Commun. 2021 Nov 1;12(1):6276. doi: 10.1038/s41467-021-26502-6. Nat Commun. 2021. PMID: 34725325 Free PMC article.

2

RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.

Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA. Bauer JA, et al. Among authors: lehmann bd. Breast Cancer Res. 2010;12(3):R41. doi: 10.1186/bcr2595. Epub 2010 Jun 24. Breast Cancer Res. 2010. PMID: 20576088 Free PMC article.

3

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Lehmann BD, et al. J Clin Invest. 2011 Jul;121(7):2750-67. doi: 10.1172/JCI45014. J Clin Invest. 2011. PMID: 21633166 Free PMC article.

4

TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.

Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, Pietenpol JA. Chen X, et al. Among authors: lehmann bd. Cancer Inform. 2012;11:147-56. doi: 10.4137/CIN.S9983. Epub 2012 Jul 24. Cancer Inform. 2012. PMID: 22872785 Free PMC article.

5

Targeting mutant p53 in human tumors.

Lehmann BD, Pietenpol JA. Lehmann BD, et al. J Clin Oncol. 2012 Oct 10;30(29):3648-50. doi: 10.1200/JCO.2012.44.0412. Epub 2012 Sep 10. J Clin Oncol. 2012. PMID: 22965952 Review. No abstract available.

6

Patient-derived breast tumor xenografts facilitating personalized cancer therapy.

Landis MD, Lehmann BD, Pietenpol JA, Chang JC. Landis MD, et al. Among authors: lehmann bd. Breast Cancer Res. 2013 Jan 22;15(1):201. doi: 10.1186/bcr3355. Breast Cancer Res. 2013. PMID: 23339383 Free PMC article. Review.

7

Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.

Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, Pietenpol JA, Shao ZM, Symmans WF, Chang JC. Yu KD, et al. Among authors: lehmann bd. Clin Cancer Res. 2013 May 15;19(10):2723-33. doi: 10.1158/1078-0432.CCR-12-2986. Epub 2013 Apr 2. Clin Cancer Res. 2013. PMID: 23549873 Free PMC article.

8

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.

Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Masuda H, et al. Among authors: lehmann bd. Clin Cancer Res. 2013 Oct 1;19(19):5533-40. doi: 10.1158/1078-0432.CCR-13-0799. Epub 2013 Aug 15. Clin Cancer Res. 2013. PMID: 23948975 Free PMC article.

9

Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.

Lehmann BD, Pietenpol JA. Lehmann BD, et al. J Pathol. 2014 Jan;232(2):142-50. doi: 10.1002/path.4280. J Pathol. 2014. PMID: 24114677 Free PMC article. Review.

10

BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.

Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W. Hutchinson KE, et al. Among authors: lehmann bd. Clin Cancer Res. 2013 Dec 15;19(24):6696-702. doi: 10.1158/1078-0432.CCR-13-1746. Clin Cancer Res. 2013. PMID: 24345920 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters